---
schema_version: "secwatch.filing_event.v1"
accession: "0001386570-26-000031"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:34:46.698989+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Niagen Bioscience Q1 net sales $31.5M (+3% YoY); net income $6.3M up from $5.1M

## Summary
- Gross margin 63.5%; adjusted EBITDA $3.8M vs $4.9M year ago.
- Launched clinician-directed telehealth platform Niagen Plus and first cruise ship clinic partnership.
- Completed divestiture of Analytical Reference Standards segment to LGC Standards in Feb 2026.
- Board approved $20M share repurchase program; repurchased $2.4M in Q1.
- FY 2026 G&A outlook improved to +$3-4M vs prior +$4-5M; sales & marketing investment to rise.

## SEC filing metadata
- accession: 0001386570-26-000031
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000031/0001386570-26-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000031/cdxc-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001386570-26-000031
- JSON: https://secwatch.observer/filing/0001386570-26-000031.json
- Plain text: https://secwatch.observer/filing/0001386570-26-000031.txt

## Source-grounded claims
- claim_id: 28079bd6b371846ae571376be4f336622967664f
  claim: Niagen Bioscience, Inc. reported first quarter of 2026 results: revenue $31.5 million, net income $6.3 million, EPS $0.08 and $0.07, respectively. Guidance reaffirmed.
  evidence_excerpt: Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million LOS ANGELES, CA - May 6, 2026 - Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000031/0001386570-26-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.